Xeltis’ polymers have shown superior pro-healing response and no calcification compared to conventional biological heart valve devices in preclinical trial…
adminAugust 6, 2021
Keep up to date with all of our latest news and events
Use the filters to find Publications, Featured News, Clinical Trials and more.
Promising early outcomes from two clinical trials of Xeltis pulmonary valve confirm the excellent safety and performance of its bio-restorative…
adminMarch 12, 2021
Xeltis has been selected with three other Swiss companies to illustrate how medtech innovation can pave new ways to improve…
adminFebruary 25, 2021
Xeltis closed a €10.5 million Series D financing round to support its vascular and valve trial programs this week. The…
adminSeptember 5, 2019
Peer-reviewed journal Cardiovascular Pathology published positive one-year in-vivo data on Xeltis’ RestoreX™ technology platform in its latest issue. According to…
adminMarch 8, 2019
Results from preclinical trials of Xeltis restorative coronary artery bypass graft XABG showed superior performance of the Xeltis graft compared…
Content TeamMarch 11, 2022
Press Releases
Xeltis starts pivotal clinical trial with first ever restorative synthetic hemodialysis access graft
Media
ETR Powered Platform
Endogenous Tissue Restoration Animation
Pulmonary Heart Valve
Endogenous Tissue Restoration Animation
Prof. Mauro Gargiulo
The aXess EU Pivotal Trial
Professor Thierry Carrel
Xeltis’ technology
Martijn Cox
Xeltis’ Co-founder on ETR
Professor Jean-Marie Lehn
Nobel Laureate Professor Lehn visits Xeltis
A Patient’s Perspective
An interview with Stefan
Global Impact of Heart Valve Disease
Professor Christian M. Spaulding
